<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04968951</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 18-1464</org_study_id>
    <nct_id>NCT04968951</nct_id>
  </id_info>
  <brief_title>Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)</brief_title>
  <acronym>REFOCUS</acronym>
  <official_title>REFOCUS: Refined Fecal Microbiota Transplantation (FMT) Delivered by Oral Capsules for Induction of Remission in Mild to Moderate Ulcerative Colitis - a Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ari M Grinspan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers intend to prospectively study the safety, clinical efficacy and microbial&#xD;
      outcomes in patients with recently diagnosed UC with FMT capsule therapy derived from&#xD;
      pre-defined donors. Donors will be specifically screened for Fusobacterium and Sutterella&#xD;
      species as well as for global diversity. It is unknown if treatment with antibiotics before&#xD;
      FMT improves the engraftment and/or efficacy of FMT in UC, therefore the researchers plan to&#xD;
      randomize subjects to receive pre-treatment with antibiotics or not before FMT therapy. The&#xD;
      research team enroll patients from The Susan and Leonard Feinstein IBD Center and our&#xD;
      established early diagnosis clinic at Mount Sinai Hospital (MSH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label two arm pilot study to measure the safety, microbiological and clinical&#xD;
      impacts of FMT in patients with ulcerative colitis. The researchers will prospectively enroll&#xD;
      16 UC patients (up to 20 subjects accounting for subjects dropping out) with moderate-severe&#xD;
      disease from one tertiary care referral center. The overall objective of the study is to&#xD;
      collect robust clinical data and create a tissue repository including blood, stool and&#xD;
      biopsies to understand the safety, efficacy and microbial changes FMT has on UC patients. The&#xD;
      central hypothesis is that pre-defined oral capsule administered FMT is safe and effective&#xD;
      for the treatment of UC.&#xD;
&#xD;
      Objectives: To determine the tolerability, feasibility, and safety of using fecal microbiota&#xD;
      transplantation orally as an induction agent for patients with ulcerative colitis. To&#xD;
      determine whether fecal microbiota transplantation (FMT) delivered via oral capsules can&#xD;
      induce clinical remission in patients with mild to moderate ulcerative colitis. Assess&#xD;
      whether pretreatment with antibiotics improves engraftment and efficacy of FMT in UC. To&#xD;
      characterize the impact of orally administered FMT on the microbiota of patients with&#xD;
      ulcerative colitis, particularly those changes associated with response or lack of response.&#xD;
&#xD;
      Study Outcomes: Clinical remission at Week 8, defined as: Steroid-free clinical remission&#xD;
      (Total Mayo less 2) and Endoscopic remission (Mayo endoscopic subscore 0 or 1)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to one of two groups. One group will be assigned to receive pre-treatment with antibiotics before Fecal Microbiota Transportation. The other group will be assigned to receive pre-treatment without antibiotics (with placebo) before Fecal Microbiota Transplantation.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Antibiotics and placebo will be disguised</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with an adverse</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Safety as measured by proportion of participants with an adverse event through week 8</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with a severe adverse</measure>
    <time_frame>8 Weeks</time_frame>
    <description>Safety as measured by proportion of participants with a severe adverse event through week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients requiring escalation of medical therapies</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of patients requiring escalation of medical therapies based on clinical relapse. Clinical relapse is defined by requiring additional medical therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieve Mayo score 0 or 1</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients with initial Mayo 2/3 disease at flexible sigmoidoscopy that achieve endoscopic improvement (Mayo score 0 or 1). The Mayo Score is a composite of subscores (each rated 0-3) from four categories, including stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy or colonoscopy, and physician's global assessment, with a total score ranging from 0-12, with higher score indicating worse health outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with endoscopic remission</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of patients with endoscopic remission as defined by a Mayo score of 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nancy score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change in histological score assessed by the Nancy score. The Nancy score includes 3 histologic items that define 5 grades of activity: absence of significant histologic disease, chronic inflammatory infiltrate with no acute inflammatory infiltrate, mildly active disease, moderately active disease, and severely active disease. Full score from , with higher score indicating worse health outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal calprotectin level</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change fecal calprotectin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein levels</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change C-reactive protein levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin levels</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change hemoglobin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin levels</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ESR level</measure>
    <time_frame>baseline and 8 weeks</time_frame>
    <description>Mean change erythrocyte sedimentation rate (ESR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ulcerative Colitis</condition>
  <condition>FMT</condition>
  <condition>Fecal Microbiota Transplant</condition>
  <arm_group>
    <arm_group_label>FMT with Antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive antibiotics before receiving Fecal Microbiota Transplantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo before receiving Fecal Microbiota Transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Antibiotic treatment - 250 mg every 6 hrs for 5 days</description>
    <arm_group_label>FMT with Antibiotics</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment</description>
    <arm_group_label>FMT with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Antibiotic treatment - 125 mg every 6 hrs for 5 days</description>
    <arm_group_label>FMT with Antibiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal Microbiota Transplantation</intervention_name>
    <description>Encapsulated biologically active human fecal material (donor stool) is provided in capsule form. The fecal material is homogenized with sterile saline, then pelleted and re-suspended in sterile saline/40% glycerol. Participants will receive 15 FMT capsules per day for 3 consecutive days. Capsule are to be swallowed under direct supervision.</description>
    <arm_group_label>FMT with Antibiotics</arm_group_label>
    <arm_group_label>FMT with placebo</arm_group_label>
    <other_name>FMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Adults aged 18 to 75 with UC, with initial diagnosis of UC &gt;3 months prior to time of&#xD;
             study enrollment visit&#xD;
&#xD;
          -  Partial Mayo score of 4-10 with endoscopic subscore â‰¥2 on flexible sigmoidoscopy&#xD;
&#xD;
          -  Permissible UC medications include oral or rectal administered mesalamines&#xD;
&#xD;
          -  Corticosteroids must be discontinued at least 4 weeks before enrollment&#xD;
&#xD;
          -  Documented negative C. difficile and GI PCR for enteric pathogens (BioFire) testing&#xD;
             before commencement of fecal microbiota transplantation&#xD;
&#xD;
          -  Previous documentation of ulcerative colitis based on colonoscopy/flexible&#xD;
             sigmoidoscopy with compatible histology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ari Grinspan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ari Grinspan, MD</last_name>
    <phone>212-241-7757</phone>
    <email>ari.grinspan@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Josephine Mitcham, BA</last_name>
    <phone>212-824-7797</phone>
    <email>josephine.mitcham@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Grinspan, MD</last_name>
      <phone>212-241-7757</phone>
      <email>Ari.grinspan@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Josephine Mitcham, BA</last_name>
      <phone>212-824-7797</phone>
      <email>josephine.mitcham@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ari Grinspan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Ari M Grinspan</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>FMT</keyword>
  <keyword>Fecal Microbiota Transplantation</keyword>
  <keyword>Fecal Microbiota Transplant</keyword>
  <keyword>Fecal Matter Transplant</keyword>
  <keyword>Ulcerative colitis</keyword>
  <keyword>UC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

